Demyelinating Disorders of the Central Nervous System

Textbook of Clinical Neurology: Third Edition

Volumn , Issue , 2007, Pages 1103-1133

  Pirko, Istvan ^a   Noseworthy, John H ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902046400     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141603618-0.10048-7     Document Type: Chapter

References (141)

1. Ebers GC MS-An historical overview. Multiple Sclerosis 1997, Oxford University Press, Philadelphia. D.W. Paty, G.C. Ebers (Eds.).
2. Medaer R Does the history of multiple sclerosis go back as far as the 14th century?. Acta Neurol Scand 1979, 60:189-192.
3. Fredrikson S, Kam-Hansen S The 150-year anniversary of multiple sclerosis: Does its early history give an etiological clue?. Perspect Biol Med 1989, 32:237-243.
4. Rivers TM, Schwentker F Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J Exp Med 1935, 61:698-702.
5. Raine CS Morphological aspects of myelin and myelination. Myelin 1997, Plenum Press, New York. P. Morell (Ed.).
6. Tjernlund U, Cesaro P, Tournier E, et al. T-cell subsets in multiple sclerosis: A comparative study between cell surface antigens and function. Clin Immunol Immunopathol 1984, 32:185-197.
7. Wucherpfennig KW, Strominger JL Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995, 80:695-705.
8. Allegretta M, Nicklas JA, Sriram S, et al. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990, 247:718-721.
9. Lassmann H, Ransohoff RM The CD4-Th1 model for multiple sclerosis: A critical [correction of crucial] re-appraisal. Trends Immunol 2004, 25:132-137.
10. Sriram S, Steiner I Experimental allergic encephalomyelitis: A misleading model of multiple sclerosis. Ann Neurol 2005, 58:939-945.
11. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473-477.
12. Bergstrom T, Andersen O, Vahlne A Isolation of herpes simplex virus type 1 during first attack of multiple sclerosis. Ann Neurol 1989, 26:283-285.
13. Melnick JL, Seidel E, Inoue YK, et al. Isolation of virus from the spinal fluid of three patients with multiple sclerosis and one with amyotrophic lateral sclerosis. Lancet 1982, 1:830-833.
14. Challoner PB, Smith KT, Parker JD, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA 1995, 92:7440-7444.
15. Wren DR, Noble M Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody. Proc Natl Acad Sci USA 1989, 86:9025-9029.
16. Selmaj KW, Raine CS Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 1995, 45:S44-S49.
17. Lucchinetti CF, Bruck W, Lassmann H Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 2004, 56:308.
18. Peterson JW, Bo L, Mork S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001, 50:389-400.
19. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
20. Ebers GC, Sadovnick AD, Risch NJ A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995, 377:150-151.
21. Dyment DA, Ebers GC, Sadovnick AD Genetics of multiple sclerosis. Lancet Neurol 2004, 3:104-110.
22. Kurtzke JF Multiple sclerosis: Changing times. Neuroepidemiology 1991, 10:1-8.
23. Page WF, Kurtzke JF, Murphy FM, et al. Epidemiology of multiple sclerosis in U.S. veterans: V. Ancestry and the risk of multiple sclerosis. Ann Neurol 1993, 33:632-639.
24. Sheremata WA, Poskanzer DC, Withum DG, et al. Unusual occurrence on a tropical island of multiple sclerosis. Lancet 1985, 2:618.
25. Armon C, Daube JR, O'Brien PC, et al. When is an apparent excess of neurologic cases epidemiologically significant?. Neurology 1991, 41:1713-1718.
26. Riise T, Nortvedt MW, Ascherio A Smoking is a risk factor for multiple sclerosis. Neurology 2003, 61:1122-1124.
27. Franklin GM, Nelson L Environmental risk factors in multiple sclerosis: Causes, triggers, and patient autonomy. Neurology 2003, 61:1032-1034.
28. Runmarker B, Andersen O Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 1995, 118(Pt 1):253-261.
29. Paty DW, Noseworthy JH, Ebers GC Diagnosis of MS. Multiple Sclerosis. Contemporary Neurology Series 1997, Davis, Philadelphia. D.W. Paty, G.C. Ebers (Eds.).
30. Pirko I, Blauwet LK, Lesnick TG, et al. The natural history of recurrent optic neuritis. Arch Neurol 2004, 61:1401-1405.
31. McIntosh-Michaelis SA, Roberts MH, Wilkinson SM, et al. The prevalence of cognitive impairment in a community survey of multiple sclerosis. Br J Clin Psychol 1991, 30(Pt 4):333-348.
32. Lublin FD, Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
33. Poser CM, Brinar VV Epilepsy and multiple sclerosis. Epilepsy Behav 2003, 4:6-12.
34. Zein G, Berta A, Foster CS Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm 2004, 12:137-142.
35. Wynn DR, Rodriguez M, O'Fallon WM, et al. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 1990, 40:780-786.
36. Rodriguez M, Siva A, Cross SA, et al. Optic neuritis: A population-based study in Olmsted County, Minnesota. Neurology 1995, 45:244-250.
37. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993, 116(Pt 1):135-146.
38. Filippi M, van Waesberghe JH, Horsfield MA, et al. Interscanner variation in brain MRI lesion load measurements in MS: Implications for clinical trials. Neurology 1997, 49:371-377.
39. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998, 121(Pt 3):495-503.
40. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002, 346:158-164.
41. Harding AE, Sweeney MG, Miller DH, et al. Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain 1992, 115(Pt 4):979-989.
42. Natowicz MR, Bejjani B Genetic disorders that masquerade as multiple sclerosis. Am J Med Genet 1994, 49:149-169.
43. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13:227-231.
44. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
45. Offenbacher H, Fazekas F, Schmidt R, et al. Assessment of MRI criteria for a diagnosis of MS. Neurology 1993, 43:905-909.
46. Francis GS, Evans AC, Arnold DL Neuroimaging in multiple sclerosis. Neurol Clin 1995, 13:147-171.
47. Sanfilipo MP, Benedict RH, Sharma J, et al. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage 2005, 26:1068-1077.
48. Ge Y, Grossman RI, Udupa JK, et al. Magnetization transfer ratio histogram analysis of normal-appearing gray matter and normal-appearing white matter in multiple sclerosis. J Comput Assist Tomogr 2002, 26:62-68.
49. Tjoa CW, Benedict RH, Weinstock-Guttman B, et al. MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J Neurol Sci 2005, 234:17-24.
50. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: Relevance to white matter changes and disability. Neurology 2003, 60:1157-1162.
51. Ebers GC, Paty DW CSF electrophoresis in one thousand patients. Can J Neurol Sci 1980, 7:275-280.
52. Villar LM, Masjuan J, Sadaba MC, et al. Early differential diagnosis of multiple sclerosis using a new oligoclonal band test. Arch Neurol 2005, 62:574-577.
53. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria.". Ann Neurol 2005, 58:840-846.
54. Beck RW The optic neuritis treatment trial: three-year follow-up results. Arch Ophthalmol 1995, 113:136-137.
55. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001, 57:1239-1247.
56. Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989, 39:1143-1149.
57. Rodriguez M, Karnes WE, Bartleson JD, et al. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993, 43:1100-1104.
58. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878-886.
59. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005, 366:579-582.
60. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002, 58:143-146.
61. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000, 343:898-904.
62. Beck RW, Chandler DL, Cole SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002, 51:481-490.
63. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 2001, 357:1576-1582.
64. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993, 43:655-661.
65. Antonelli G, Simeoni E, Bagnato F, et al. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci 1999, 168:131-136.
66. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996, 39:285-294.
67. Gold R, Rieckmann P, Chang P, et al. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol 2005, 12:649-656.
68. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998, 352:1498-1504.
69. Li DK, Paty DW Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999, 46:197-206.
70. Brod SA, Lindsey JW, Vriesendorp FS, et al. Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS. Neurology 2001, 57:845-852.
71. Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003, 61:184-189.
72. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987, 317:408-414.
73. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268-1276.
74. Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes.". Neurology 2001, 57:731-733.
75. Comi G, Filippi M, Wolinsky JS European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001, 49:290-297.
76. Wolinsky JS, Narayana PA, Johnson KP United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Mult Scler 2001, 7:33-41.
77. Markovic-Plese S, Bielekova B, Kadom N, et al. Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon beta-1b. Neurology 2003, 60:1849-1851.
78. Strasser-Fuchs S, Fazekas F, Deisenhammer F, et al. The Austrian Immunoglobulin in MS (AIMS) study: final analysis. Mult Scler 2000, 6(Suppl 2):S9-S13.
79. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001, 56:1514-1522.
80. Noseworthy JH, O'Brien PC, Weinshenker BG, et al. IV immunoglobulin does not reverse established weakness in MS. Neurology 2000, 55:1135-1143.
81. Stangel M, Boegner F, Klatt CH, et al. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000, 68:89-92.
82. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005, 64:804-810.
83. Noseworthy JH, Kirkpatrick P Natalizumab. Nat Rev Drug Discov 2005, 4:101-102.
84. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348:15-23.
85. Kleinschmidt-DeMasters BK, Tyler KL Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353:369-374.
86. Barkhof F, van Waesberghe JH, Filippi M, et al. T(1) hypointense lesions in secondary progressive multiple sclerosis: Effect of interferon beta-1b treatment. Brain 2001, 124:1396-1402.
87. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998, 352:1491-1497.
88. Miller DH, Molyneux PD, Barker GJ, et al. Effect of interferon-beta-1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta-1b in secondary progressive multiple sclerosis. Ann Neurol 1999, 46:850-859.
89. Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001, 57:1969-1975.
90. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000, 123(Pt 11):2256-2263.
91. Li DK, Zhao GJ, Paty DW Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001, 56:1505-1513.
92. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials. Neurology 2004, 63:1779-1787.
93. Filippi M, Rocca MA, Pagani E, et al. European study on intravenous immunoglobulin in multiple sclerosis: Results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol 2004, 61:1409-1412.
94. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000, 343:1430-1438.
95. Hartung HP, Gonsette R Mitoxantrone in progressive MS: A placebo controlled, randomized, observer blinded phase III multi-center study: Clinical results. Mult Scler 1998, 4:325.
96. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997, 62:112-118.
97. Ghalie RG, Mauch E, Edan G, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002, 8:441-445.
98. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025.
99. Krapf H, Morrissey SP, Zenker O, et al. Effect of mitoxantrone on MRI in progressive MS: Results of the MIMS trial. Neurology 2005, 65:690-695.
100. Leary SM, Thompson AJ Interferon beta-1a in primary progressive multiple sclerosis. J Neurol Sci 2003, 206:215-216.
101. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991, 338:1051-1055.
102. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995, 37:30-40.
103. Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994, 344:9-13.
104. Rice GP, Filippi M, Comi G Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000, 54:1145-1155.
105. Fassas A, Anagnostopoulos A, Kazis A, et al. Autologous stem cell transplantation in progressive multiple sclerosis-An interim analysis of efficacy. J Clin Immunol 2000, 20:24-30.
106. Wiles CM, Newcombe RG, Fuller KJ, et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 2001, 70:174-179.
107. Wingerchuk DM, Benarroch EE, O'Brien PC, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005, 64:1267-1269.
108. Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004, 63:1579-1585.
109. Alusi SH, Aziz TZ, Glickman S, et al. Stereotactic lesional surgery for the treatment of tremor in multiple sclerosis: A prospective case-controlled study. Brain 2001, 124:1576-1589.
110. Alusi SH, Worthington J, Glickman S, et al. A study of tremor in multiple sclerosis. Brain 2001, 124:720-730.
111. Carter JL, Noseworthy JH Ventilatory dysfunction in multiple sclerosis. Clin Chest Med 1994, 15:693-703.
112. Boskovic R, Wide R, Wolpin J, et al. The reproductive effects of beta interferon therapy in pregnancy: A longitudinal cohort. Neurology 2005, 65:807-811.
113. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain 1989, 112(Pt 1):133-146.
114. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: A 10-year follow-up study. Neurology 2004, 62:51-59.
115. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114.
116. Mandler RN, Davis LE, Jeffery DR, et al. Devic's neuromyelitis optica: A clinicopathological study of 8 patients. Ann Neurol 1993, 34:162-168.
117. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
118. Wingerchuk DM, Weinshenker BG Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology 2003, 60:848-853.
119. Filippi M, Rocca MA, Moiola L, et al. MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica. Neurology 1999, 53:1705-1710.
120. O'Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996, 60:382-387.
121. Wingerchuk DM, Weinshenker BG Neuromyelitis optica. Curr Treat Options Neurol 2005, 7:173-182.
122. Schwarz S, Mohr A, Knauth M, et al. Acute disseminated encephalomyelitis: A follow-up study of 40 adult patients. Neurology 2001, 56:1313-1318.
123. Hartung HP, Grossman RI ADEM: Distinct disease or part of the MS spectrum?. Neurology 2001, 56:1257-1260.
124. Hynson JL, Kornberg AJ, Coleman LT, et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001, 56:1308-1312.
125. Kesselring J, Miller DH, Robb SA, et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain 1990, 113(Pt 2):291-302.
126. The Cochrane Library 2005, (Issue 2). Cochrane Multiple Sclerosis Group,: Abstracts of Cochrane Reviews, Available at. http://www.cochrane.org/reviews/en/topics/79.html.
127. Dyment DA, Ebers GC, Sadovnick AD Genetics of multiple sclerosis. Lancet Neurol 2004, 3(2):104-110.
128. Frohman EM, Goodin DS, Calabresi PA, et al. Utility of MRI in suspected MS. Neurology 2003, 61:602-611.
129. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. Neurology 2003, 61:1332-1338.
130. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis. Neurology 2002, 58:169-178.
131. Kantarci OH, Weinshenker BG Natural history of multiple sclerosis. Neurol Clin 2005, 23(1):17-38.
132. Koch-Henriksen N, Sørensen PS, Christensen T, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006, 66:1056-1060.
133. Kutzelnigg A, Lassmann H Cortical lesions and brain atrophy in MS. J Neurol Sci 2005, 233(1-2):55-59.
134. Lucchinetti CF, Parisi J, Bruck W The pathology of multiple sclerosis. Neurol Clin 2005, 23(1):77-105.
135. Noseworthy JH Management of multiple sclerosis: current trials and future options. Curr Opin Neurol 2003, 16(3):289-297.
136. Noseworthy J, Kappos L, Daumer M Competing interests in multiple sclerosis research. Lancet 2003, 361(9354):350-351.
137. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria.". Ann Neurol 2005, 58(6):840-846.
138. Rutschmann OT, McCrory DC, Matchar DB Immunization and multiple sclerosis: A summary of published evidence and recommendations. Neurology 2002, 59:1837-1843.
139. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG Revised diagnostic criteria for neuromyelitisi optica. Neurology 2006, 66:1485-1489.
140. Wingerchuk DM, Weinshenker BG Neuromyelitis optica. Curr Treat Options Neurol 2005, 7(3):173-182.
141. Wingerchuk DM, Noseworthy JH Randomized controlled trials to assess therapies for multiple sclerosis. Neurology 2002, 58(8 Suppl 4):S40-S48.